Literature DB >> 14638904

Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis.

Rujun Gong1, Abdalla Rifai, Evelyn M Tolbert, Jason N Centracchio, Lance D Dworkin.   

Abstract

Evidence suggests that hepatocyte growth factor (HGF) ameliorates renal fibrosis in animal models of chronic renal disease by promoting extracellular matrix catabolism. This study examined the molecular mechanisms of HGF-induced alterations in matrix degradation both in vitro and in vivo. In vitro, HGF increased the collagen catabolizing activity of human proximal tubular epithelial cells (HKC) that were treated with TGF-beta1. Increased collagen catabolism was associated with enhanced activity of both matrix metalloproteinases (MMP) and plasminogen activators (PA)/plasmin proteolytic pathways. HGF abrogated TGF-beta1-induced production of the profibrotic tissue inhibitor of metalloproteinase-2 (TIMP-2) and plasminogen activator inhibitor-1 (PAI-1). In addition, HGF induced the production of MMP-9. In vivo, continuous infusion of HGF in the rat remnant kidney model ameliorated renal fibrosis and tubulointerstitial collagen deposition. This was associated with increased tubular expression of MMP-9, enhanced in situ gelatinolytic activity, partially restored plasmin activity and decreased expression of TIMP-2 and PAI-1 in tubular cells, and upregulation of renal TIMP-3 expression. Conversely, blocking of endogenous HGF by an anti-HGF neutralizing antibody increased renal fibrosis and interstitial collagen. This was accompanied by decreased tubular expression of MMP-9, less in situ proteolytic activity, and elevated expression of TIMP-2 and PAI-1 in tubular cells. Collectively, these findings demonstrate that HGF ameliorates renal fibrosis by enhancing extracellular matrix catabolism via both MMP and the PA/plasmin proteolytic pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638904     DOI: 10.1097/01.asn.0000098686.72971.db

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  19 in total

1.  The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

Authors:  Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

2.  Evaluation of MYOC, ACAN, HGF, and MET as candidate genes for high myopia in a Han Chinese population.

Authors:  Xian Yang; Xiaoqi Liu; Jie Peng; Hong Zheng; Fang Lu; Bo Gong; Guiqiu Zhao; Yan Meng; Hongzai Guan; Meizhen Ning; Zhenglin Yang; Yi Shi
Journal:  Genet Test Mol Biomarkers       Date:  2014-04-25

3.  Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma.

Authors:  M Matsushita; T Yamamoto; K Nishioka
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  Glycogen synthase kinase 3β orchestrates microtubule remodeling in compensatory glomerular adaptation to podocyte depletion.

Authors:  Weiwei Xu; Yan Ge; Zhihong Liu; Rujun Gong
Journal:  J Biol Chem       Date:  2014-12-02       Impact factor: 5.157

5.  Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.

Authors:  Chongxiang Xiong; Yingjie Guan; Xiaoxu Zhou; Lirong Liu; Michelle A Zhuang; Wei Zhang; Yunhe Zhang; Monica V Masucci; George Bayliss; Ting C Zhao; Shougang Zhuang
Journal:  FASEB J       Date:  2019-04-05       Impact factor: 5.191

6.  Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells.

Authors:  Rujun Gong; Abdalla Rifai; Yan Ge; Shan Chen; Lance D Dworkin
Journal:  J Biol Chem       Date:  2008-01-17       Impact factor: 5.157

Review 7.  Progression and regression in renal vascular and glomerular fibrosis.

Authors:  Christos Chatziantoniou; Jean-Jacques Boffa; Pierre-Louis Tharaux; Martin Flamant; Pierre Ronco; Jean-Claude Dussaule
Journal:  Int J Exp Pathol       Date:  2004-02       Impact factor: 1.925

8.  Astragalus mongholicus ameliorates renal fibrosis by modulating HGF and TGF-beta in rats with unilateral ureteral obstruction.

Authors:  Chuan Zuo; Xi-sheng Xie; Hong-yu Qiu; Yao Deng; Da Zhu; Jun-ming Fan
Journal:  J Zhejiang Univ Sci B       Date:  2009-05       Impact factor: 3.066

Review 9.  Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis.

Authors:  William McKleroy; Ting-Hein Lee; Kamran Atabai
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-05       Impact factor: 5.464

Review 10.  Novel targets of antifibrotic and anti-inflammatory treatment in CKD.

Authors:  Anne-Emilie Declèves; Kumar Sharma
Journal:  Nat Rev Nephrol       Date:  2014-03-25       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.